The US Preventive Services Task Force is recommending screening all adults for illicit drug use; Senator Chuck Grassley, R-Iowa, is asking the FDA to perform more unannounced inspections of foreign drug manufacturing facilities; 5 years after Congress passed a law to reduce unneccessary diagnostic imaging tests, the law has yet to be implemented.
The US Preventive Services Task Force (USPSTF) has issued a draft recommendation statement recommending that all adults aged 18 years and older be screened for illicit drug use. The task force cited a 2017 national survey in which an estimated 11.5% of adults reported current use of illicit drugs. Illicit drug use is more often reported among young adults aged 18 to 25 years (24.2%) than in older adults (9.5%) or in adolescents aged 12 to 17 years (7.9%). Citing insufficient evidence, USPSTF said it could not assess the benefits and harms of screening for illicit drug use in adolescents.Following HHS’ outlining of a plan to create 2 potential pathways to allow states and other entities to import some prescription drugs intended for foreign markets, Senator Chuck Grassley, R-Iowa, is asking the FDA to perform more unannounced inspections of foreign drug manufacturing facilities. Writing to HHS Secretary Alex Azar and Acting FDA Commissioner Ned Sharpless, MD, Grassley explained that he had learned that the FDA does not track in its databases whether a foreign inspection was subject to an announced or unannounced visit, reported The Center for Biosimilars®.
In 2014, Congress passed a law to reduce unnecessary magnetic resonance imaging, computed tomography scans, and other expensive diagnostic imaging tests that could both harm patients and waste money. However, 5 years later, the law has yet to be implemented and the Trump administration has delayed the law until January 2020, 2 years later than originally planned, according to Kaiser Health News. Even with the 2020 start date, CMS has scheduled next year as a “testing” period, meaning that the agency will still pay for an exam even if the physician doesn’t check the guidelines.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More